home products and services resources Library News White Papers + Fact Sheets
about Jobs Research BV Cycloton VU
Unfortunately, as of 2020, Iodine-124 (124I) is no longer produced by us.
If you have any questions, do not hesitate to contact our Product Specialist, Renske Raaphorst. You can reach her at:
Tel: +31 20 4444380
+31 20 44 49 123
“The Future of Immuno-
in Drug Development. Zirconium-89 and Iodine-124 as Key Factors in Molecular Imaging”
. Physical Properties, Production, Labeling and Applications of
Tomorrow, our managing director will give a talk at the molecular imaging conference in Groningen
Research from the university of Duisburg shows high level of agreement between 124I-PET and 131I-imaging
We are hiring! Two new interesting job postings:
Featured Articles Van Dongen, G. A., M. C. Huisman, R. Boellaard, Hendrikse N. Harry, A. D. Windhorst, G. W. Visser, C. F. Molthoff, and D. J. Vugts. “89Zr-immuno- PET for imaging of long circulating drugs and disease targets: why, how and when to be applied?.” The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine ( AIMN)[and] the International Association of Radiopharmacology ( IAR),[and] Section of the Society of.. 59, no. 1 (2015): 18-38. Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O’Keefe G, Chan JG, Young K, Tochon-Danguy H, Masters CL, Rowe CC, Comparison of 11C-PiB and 18F-florbetaben for Aß imaging in ageing and Alzheimer’s disease, Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):983-9. Epub 2012 Mar 8. Rizvi SN, Visser OJ, Vosjan MJ, van Lingen A, Hoekstra OS, Zijlstra JM, Huijgens PC, van Dongen GA, Lubberink M. Biodistribution, radiation dosimetry and scouting of (90)Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using (89)Zr-ibritumomab tiuxetan and
PET. Eur J Nucl Med Mol Imaging. 2012 Jan 5. (Epub ahead of print) Have you spotted relevant or interesting new research? Let us know!